Effectiveness of Hepatitis E Vaccine in High-Risk Adults
Study Overview
This study looked at how well the hepatitis E vaccine works in adults who have chronic hepatitis B (CHB). We focused on individuals who tested positive for hepatitis B surface antigen (HBsAg).
Key Findings
We analyzed data from 2,926 HBsAg-positive adults, aged 49 on average, from a hepatitis surveillance system in Jiangsu, China, between 2007 and 2017. The study compared 96 confirmed hepatitis E cases with 2,830 controls who did not have the disease.
The results showed that the HEV 239 vaccine significantly reduced the risk of hepatitis E in HBsAg-positive individuals, with an effectiveness rate of:
- 72.1% (95% confidence interval: 11.2-91.2)
- 81.5% (95% confidence interval: 35.9-94.6) among phase 3 trial participants.
This indicates that the HEV 239 vaccine is very effective for adults with HBsAg, supporting its recommendation for use in this group.
Importance of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. They help translate research into practical medical solutions.
Practical Solutions for Healthcare Providers
DocSym, our AI-driven platform, offers:
- A consolidated knowledge base that includes ICD-11 standards and clinical protocols.
- Mobile apps for scheduling, treatment monitoring, and telemedicine to streamline patient care.
By integrating AI, clinics can improve workflows, enhance patient outcomes, and reduce paperwork. Learn more about our solutions at aidevmd.com.
